Home
News
Your Voice
Links
Jobs
Sitemap
Contact
YOU ARE HERE: >
Kernow Clinical Commissioning Group
>
Formulary Information
>
Information Page
Home
Drugs
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Chapters
KCC Referral
Management System
Shared Care
Guidelines
Care Home
Resources
Local Resource
Packs
Chronic Pain
in Cornwall
Diabetes Resources
Respiratory Resources
Flu Resource Pack
Patient Group Direction (PGD)
Palliative Care Resources
Search
Search Drugs
Search BNF Categories
Notes
Click to View ALL BNF
Ch1 Gastro
Ch2 Cardio
Ch3 Respiratory
Ch4 CNS
Ch5 Infections
Ch6 Endocrine
Ch7 Obs & Gynae
Ch8 Malignant Disease
Ch9 Nutrition & Blood
Ch10 Muscuskeletal
Ch11 Eye
Ch12 Ear, Nose, Oropharynx
Ch13 Skin
Ch14 Immunological
Ch15 Anaesthesia
Ch19 Other Dugs
ch20 Dressings
ch21 Appliances
ch22 Incontinence appliances
ch23 Stoma appliances
>>
1. Dyspep&Gastro-Oesophageal Reflux Disease
2. Antispasmod.&Other Drgs Alt.Gut Motility
3. Antisecretory Drugs+Mucosal Protectants
4. Acute Diarrhoea
5. Chronic Bowel Disorders
6. Laxatives
7. Local Prepn for Anal & Rectal Disorders
8. Stoma Care
9. Drugs Affecting Intestinal Secretions
>>
0. Chronic Bowel Disorders
0. Aminosalicylates
0. Corticosteroids
0. Drugs affecting the immune response
0. Food allergy
(Click to View Drug List)
Cost
Cost
Packs
Packs
Items
Items
Loading…
Summary:
Formulary Notes (BNF Chapter)
Formulary Notes (BNF Chapter)
NICE Guidance (15)
NICE Guidance (15)
Other Links (0)
Other Links (0)
Important Local Documents (0)
Important Local Documents (0)
Notes for: Gastro-intestinal system
Last edited [08/08/2024 14:40:46]
National clinical constipation pathway for primary care for children 2023
Proton Pump Inhibitor (PPI) Prescribing in Paediatric Patients Clinical Guideline (RCHT)
NICE Guidance (BNF Sub Paragraph Level) for - Drugs affecting the immune response
30/09/2015
TA187 - Infliximab (review) and adalimumab for the treatment of Crohn's disease
30/09/2015
TA 163 - Infliximab for acute exacerbations of ulcerative colitis
30/09/2015
TA352 - Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy
30/09/2015
TA342 - Vedolizumab for treating moderately to severely active ulcerative colitis
30/05/2019
TA547 - Tofacitinib for moderately to severely active ulcerative colitis
30/05/2019
TA456 - Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
NICE Guidance (BNF Section Level) for - Chronic Bowel Disorders
30/05/2019
NG130 - Ulcerative colitis: management
30/05/2019
NG129 - Crohn’s disease: management
05/09/2022
TA792 Filgotinib for treating moderately to severely active ulcerative colitis
09/01/2023
TA856 Upadacitinib for treating moderately to severely active ulcerative colitis
15/11/2023
TA888 Risankizumab for previously treated moderately to severely active Crohn's disease
30/11/2023
TA925 Mirikizumab for treating moderately to severely active ulcerative colitis
NICE Guidance (BNF Chapter Level) for - Gastro-intestinal system
13/08/2021
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
23/04/2024
Obesity: identification, assessment and management CG189
23/04/2024
Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management CG184
No links available
No files available
Loading…
Cornwall Joint Formulary Recommended Choices
(...Top)
Displaying 3 Drugs
Key:
First Line Drugs
Second Line Drugs
Specialist advised
Specialist Initiated Drugs
Hospital Only Drugs
Discouraged
No comment available
Name
Tariff
BNF Sub Paragraph
Prednisolone E/C Tablet
2.5 mg E/C tab Pack of 28
£1.05
Drugs affecting the immune response
Vedolizumab
108 mg/0.68ml pre-filled syringes (Entyvio tariff) Pack of 1
-
Drugs affecting the immune response
Vedolizumab (Entyvio )
300 300mg powder for concentrate for solution for infusion vials Pack of 1
-
Drugs affecting the immune response
© Kernow Clinical Commissioning Group 2024 - All Rights Reserved
The Sedgemoor Centre, Priory Road, St Austell, Cornwall, PL25 5AS